Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating β-cell proliferation, inducing islet reg...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1483792/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593940218380288 |
|---|---|
| author | Xu He Xu He Xu He Wei Zhao Wei Zhao PeiHang Li PeiHang Li YinJiang Zhang YinJiang Zhang GuoHua Li HongYu Su BiNan Lu BiNan Lu ZongRan Pang ZongRan Pang |
| author_facet | Xu He Xu He Xu He Wei Zhao Wei Zhao PeiHang Li PeiHang Li YinJiang Zhang YinJiang Zhang GuoHua Li HongYu Su BiNan Lu BiNan Lu ZongRan Pang ZongRan Pang |
| author_sort | Xu He |
| collection | DOAJ |
| description | Glucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating β-cell proliferation, inducing islet regeneration, inhibiting β-cell apoptosis and glucagon release, delaying gastric emptying and controlling appetite, etc. It plays a role through a specific GLP-1 receptor (GLP-1R) distributed in many organs or tissues and participates in the regulation of glucose homeostasis in the body. GLP-1 receptor agonists (GLP-1RAs) has the similar physiological function of GLP-1. Because of its structural difference from natural GLP-1, it is not easy to be degraded by dipeptidyl peptidase-4 (DPP-4), thus prolonging the action time. GLP-1RAs have been recognized as a new type of hypoglycemic drugs and widely used in the treatment of type 2 diabetes mellitus (T2DM). Compared with other non-insulin hypoglycemic drugs, it can not only effectively reduce blood glucose and glycosylated hemoglobin (HbA1c), but also protect cardiovascular system, nervous system and kidney function without causing hypoglycemia and weight gain. Therefore, GLP-1RAs has good application prospects and potential for further development. |
| format | Article |
| id | doaj-art-8664fc09b8984dcc8580000e359df9a7 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-8664fc09b8984dcc8580000e359df9a72025-01-20T07:20:09ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14837921483792Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitusXu He0Xu He1Xu He2Wei Zhao3Wei Zhao4PeiHang Li5PeiHang Li6YinJiang Zhang7YinJiang Zhang8GuoHua Li9HongYu Su10BiNan Lu11BiNan Lu12ZongRan Pang13ZongRan Pang14School of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaPharmacy Department, People’s Hospital of Dali Bai Autonomous Prefecture, Dali, ChinaSchool of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaSchool of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaSchool of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaPharmacy Department, People’s Hospital of Dali Bai Autonomous Prefecture, Dali, ChinaGraduate School, Chengde Medical College, Chengde, ChinaSchool of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaSchool of Pharmacy, Minzu University of China, Beijing, ChinaKey Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, ChinaGlucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating β-cell proliferation, inducing islet regeneration, inhibiting β-cell apoptosis and glucagon release, delaying gastric emptying and controlling appetite, etc. It plays a role through a specific GLP-1 receptor (GLP-1R) distributed in many organs or tissues and participates in the regulation of glucose homeostasis in the body. GLP-1 receptor agonists (GLP-1RAs) has the similar physiological function of GLP-1. Because of its structural difference from natural GLP-1, it is not easy to be degraded by dipeptidyl peptidase-4 (DPP-4), thus prolonging the action time. GLP-1RAs have been recognized as a new type of hypoglycemic drugs and widely used in the treatment of type 2 diabetes mellitus (T2DM). Compared with other non-insulin hypoglycemic drugs, it can not only effectively reduce blood glucose and glycosylated hemoglobin (HbA1c), but also protect cardiovascular system, nervous system and kidney function without causing hypoglycemia and weight gain. Therefore, GLP-1RAs has good application prospects and potential for further development.https://www.frontiersin.org/articles/10.3389/fphar.2024.1483792/fullGLP-1GLP-1RAsT2DMglucosemechanism |
| spellingShingle | Xu He Xu He Xu He Wei Zhao Wei Zhao PeiHang Li PeiHang Li YinJiang Zhang YinJiang Zhang GuoHua Li HongYu Su BiNan Lu BiNan Lu ZongRan Pang ZongRan Pang Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus Frontiers in Pharmacology GLP-1 GLP-1RAs T2DM glucose mechanism |
| title | Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus |
| title_full | Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus |
| title_fullStr | Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus |
| title_full_unstemmed | Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus |
| title_short | Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus |
| title_sort | research progress of glp 1ras in the treatment of type 2 diabetes mellitus |
| topic | GLP-1 GLP-1RAs T2DM glucose mechanism |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1483792/full |
| work_keys_str_mv | AT xuhe researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT xuhe researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT xuhe researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT weizhao researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT weizhao researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT peihangli researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT peihangli researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT yinjiangzhang researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT yinjiangzhang researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT guohuali researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT hongyusu researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT binanlu researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT binanlu researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT zongranpang researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus AT zongranpang researchprogressofglp1rasinthetreatmentoftype2diabetesmellitus |